Is bimetinib/bemetinib an imported drug or a domestic drug?

Binimetinib is a MEK inhibitor targeted anti-cancer drug that mainly interferes with the growth and proliferation of cancer cells by inhibiting MEK1/2 kinase in the MAPK pathway. This pathway is highly active in a variety of tumor types, especially malignant melanoma and colorectal cancer carrying BRAF V600E or NRAS mutations.

Up to now, bimetinib is an imported original drug and has not been officially registered and marketed in mainland China, nor has it been approved for commercial sales by the National Medical Products Administration (NMPA). Therefore, in the domestic market, patients cannot obtain the drug through regular pharmacies or hospital channels and can only rely on cross-border drug purchase or overseas medical treatment.

At the same time, no domestic company has obtained a generic drug approval number for bimetinib, which means that there is currently no legal domestic version of the generic drug on the market. This not only reflects the lag in the domestic clinical trials and registration approval process of the drug, but also shows that its potential market is still in the initial development stage.

In addition, since most of the clinical use scenarios of bimetinib are targeted therapies for tumors associated withBRAF or NRAS mutations, this type of precision medicine program itself has high requirements for molecular testing, which also makes its use threshold relatively high. Therefore, in current domestic clinical practice, doctors mostly choose alternative drugs (such as dabrafenib, trametinib, etc.).

It is worth mentioning that although bimetinib has not yet been launched in China, with the continuous promotion of precision medicine and personalized treatment concepts, as well as the country's policy support to encourage the import of innovative drugs, bimetinib is expected to accelerate the registration process in China in the future. If successfully approved, it will greatly enrich BRAF/MEK inhibitor treatment options and bring more targeted treatment options to patients with specific gene mutations.

Reference materials:https://go.drugbank.com/drugs/DB11967